How valve platform choice is really made
Once TAVI is on the table, the question of which platform arises. Balloon-expandable vs self-expanding, coronary access, conduction risk, calcium geometry — what the Heart Team is actually weighing.
Once TAVI is established as the preferred approach, platform selection begins. This is not a brand preference — it is an anatomically and strategically driven decision, shaped by vessel anatomy, coronary anatomy, calcium distribution, and the patient's likely future.
Key takeaway
No single platform fits all patients. The decision integrates annular geometry, calcium pattern, coronary access risk, pacemaker risk, and lifetime strategy — and it requires imaging, team experience, and patient context that cannot be reduced to a simple rule.
Key points
- Balloon-expandable valves offer precise deployment and generally lower pacemaker rates; repositioning is limited before full deployment.
- Self-expanding valves are repositionable and retrievable; historically higher pacemaker rates, though this varies by generation and technique.
- Coronary access after TAVI depends on valve height, commissural alignment, and native anatomy — and must be anticipated at the time of valve selection.
- Annular and LVOT calcium distribution can affect sealing, paravalvular leak risk, and annular injury risk.
- Lifetime strategy — including valve-in-valve feasibility — should be planned before the index procedure, not after.
- Operator and institutional experience with specific platforms legitimately influences outcomes.
Scope of this article
This article addresses platform selection within TAVI, not the SAVR vs TAVI choice. Indication first — platform is a downstream question. No single device is recommended here; the goal is to explain what the Heart Team is weighing.
This is not a one-click decision
Heart Team discussions about platform selection can be lengthy. That is appropriate — the decision integrates anatomical imaging (CT), functional data, patient history, and institutional experience. Treating it as a preference question misses the clinical substance. The following sections outline the major variables that drive the choice.
Balloon-expandable vs self-expanding: the broad idea
Balloon-expandable valves (exemplified by the Edwards Sapien family) are deployed by inflating a balloon to a specified diameter. Deployment is precise, but repositioning after partial deployment is limited. The frame has high radial force, which can be advantageous in calcified annuli. Self-expanding valves (exemplified by the Medtronic Evolut and Boston Scientific Navitor families) are deployed by retracting a sheath; they can be retrieved and repositioned before full release. The self-expanding nitinol frame applies continuous radial force and adapts to the anatomy over time.
Coronary access matters
Future coronary catheterization after TAVI may be needed — for revascularization of native coronary disease or in patients who develop de novo disease over time. Coronary access after TAVI depends on the height of the valve frame relative to the coronary ostia, the commissural alignment of the bioprosthetic leaflets relative to native sinuses, and the patient's native anatomy. Valves that sit very high in the aortic root may obstruct coronary access. Commissural alignment techniques are now used with some platforms to preserve coronary access. This is increasingly factored into pre-procedural planning.
Conduction risk and pacemaker implantation
TAVI can disrupt the conduction system, particularly the bundle of His and left bundle branch, as the valve frame passes through or adjacent to these structures. Self-expanding valves with deeper implantation have historically been associated with higher rates of permanent pacemaker implantation (PPI) — in some early series, 20–30%. Advances in technique (higher implant, shorter valve) and newer-generation devices have reduced this substantially. Balloon-expandable valves generally show lower PPI rates. Patients with pre-existing right bundle branch block are at higher risk with any TAVI approach, and this may influence platform selection or procedural technique.
Calcium distribution and annular geometry
CT-based calcium scoring and geometry assessment are now standard pre-TAVI. Heavy, circumferential calcification provides good anchoring for the valve frame but increases risk of annular injury and paravalvular leak. Asymmetric calcium — particularly calcium extending into the LVOT — affects sealing and increases the risk of paravalvular regurgitation. Bicuspid annuli are often elliptical rather than circular, which can complicate sizing and sealing with round-frame devices. Non-circular annuli may favor specific platform geometry. Extremely calcified or small/large annuli may be better suited to specific frame designs.
Lifetime strategy changes the choice
For patients with long life expectancy, the current TAVI valve is not the last valve they will receive. Valve-in-valve TAVI — placing a second transcatheter valve inside the first — is a recognized strategy for failed bioprostheses, but it requires adequate internal diameter after the index procedure. Sizing at the index procedure should account for future valve-in-valve feasibility. Surgical bioprosthetic valves are also used as TAVI landing zones, and the choice of surgical valve at SAVR can deliberately optimize for future transcatheter options.
Why team experience matters
Beyond anatomy and physiology, outcomes data consistently show that operator and institutional volume influence TAVI results. Centers with high procedural volumes show lower complication rates across platforms. More importantly, familiarity with specific device behavior — how a particular valve handles in challenging anatomy, how to recognize and respond to deployment problems in real time — is not transferable simply by reading instructions. A center with deep experience in one platform may achieve better results with that platform than a center switching between multiple systems for marginal anatomical reasons.
Pitfall: Treating platform selection as a brand preference
The platform discussion should be driven by anatomy, lifetime strategy, and team experience — not by vendor relationships or habit. When a platform is chosen, the clinical team should be able to articulate why this specific valve fits this specific patient.
Apply this in practice
Evaluate AVR indication and approach framing in the AS Intervention Navigator.
Open AS Intervention Navigator